![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients...
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.17 | -5.9649122807 | 2.85 | 2.95 | 2.5 | 74085 | 2.7267582 | CS |
4 | 0.45 | 20.1793721973 | 2.23 | 3.07 | 2.06 | 159643 | 2.6535419 | CS |
12 | 0.12 | 4.6875 | 2.56 | 3.07 | 1.91 | 143496 | 2.32165795 | CS |
26 | -17.18 | -86.5055387714 | 19.86 | 21.4 | 1.91 | 316271 | 3.64058862 | CS |
52 | -5.45 | -67.0356703567 | 8.13 | 22.22 | 1.91 | 194318 | 6.26814317 | CS |
156 | -14.17 | -84.0949554896 | 16.85 | 23.58 | 1.91 | 118840 | 7.68887755 | CS |
260 | -14.17 | -84.0949554896 | 16.85 | 23.58 | 1.91 | 118840 | 7.68887755 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions